Annovis Bio, Inc.

NYSE:ANVS Stock Report

Market Cap: US$94.9m

Annovis Bio Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Maria Maccecchini

Chief executive officer

US$808.0k

Total compensation

CEO salary percentage100.00%
CEO tenure18yrs
CEO ownership3.5%
Management average tenure4.3yrs
Board average tenure10.3yrs

Recent management updates

Recent updates

Analysis Article • May 22

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Analysis Article • Jun 25

We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 06

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 17

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Summary In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70% stock drop. The company plans to proceed with a phase 3 trial despite the lack of convincing efficacy data and significant financial constraints. Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 27

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Summary Annovis Bio's Buntanetap shows promising results in treating Alzheimer's and Parkinson's, with significant cognitive and motor function improvements in Phase 2/3 and Phase 3 trials. The drug also improved motor function in Phase 3 Parkinson’s trials, especially in advanced cases and PIGD patients. Buntanetap's mechanism of action targets neurotoxic proteins, offering symptomatic and possibly disease-modifying benefits, making it a valuable IP for combination therapies. Buntanetap showed statistically significant cognitive improvement in Phase 2/3 Alzheimer’s trials, particularly at 15mg and 30mg doses. Unfortunately, its short cash runway can't be ignored. So, I maintain a "hold" rating on ANVS until it secures more long-term financing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Summary Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy in the ITT population among positive post-hoc claims. The company intends to meet with the FDA and discuss an NDA filing, which, we believe, is currently not supported by the available evidence. Financial constraints persist, with ~$4M cash left on the balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jun 30

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Summary Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease. The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern. There is now more certainty that the Phase 2/3 trial in Alzheimer's disease failed to reach its primary endpoints. A recent CFO resignation, lack of funding and the company's wishes to conduct large further trials lead to a Strong Sell rating. Read the full article on Seeking Alpha
Seeking Alpha • May 02

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces financial challenges and may see a significant decline in stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Feb 12

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s symptoms, which could suggest that a majority of patients in the higher 20 mg (higher dose) cohort experienced an improvement. A positive topline readout for the buntanetap 20mg dose would have a positive readthrough to the Alzheimer’s results due in 2Q24. The company has the overhang of needing to raise cash imminently and faces general market skepticism. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Annovis And Alzheimer's Disease: The Best-Laid Plans

Summary Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The primary triggers for Alzheimer's disease are unrelated to amyloid, making it unlikely that Annovis' buntanetap will substantially impact disease progression. Anti-amyloid drugs only slow down the progression of Alzheimer's disease in its early stages in APOE4 carriers and may not be effective in the long-term. Read the full article on Seeking Alpha
Seeking Alpha • Jan 20

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Summary Annovis Bio has two upcoming major catalysts, a phase 2/3 AD clinical trial and a phase 3 PD clinical trial. The investigational drug, Buntanetap, is an enantiomer of a molecule previously tested for AD, with no success. We believe that the likelihood of success for Buntanetap in clinical trials is low, and if the drug fails, Annovis Bio's stock could plummet to or below its cash reserves. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Summary Annovis is expected to report data from Phase 3 and Phase 2/3 trials in Parkinson's and Alzheimer's disease, respectively. The efficacy of Annovis' lead compound, Buntanetap, is difficult to align with its proposed disease-modifying mechanism of action. Annovis has a low market cap and may need to raise capital around the upcoming topline data. Given previously seen stock volatility, I believe a good understanding of the upcoming reporting is in place. Read the full article on Seeking Alpha
Analysis Article • Sep 08

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 28

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Summary Results from the phase 3 study, using buntanetap for the treatment of patients with Parkinson's Disease, are expected to be released before the end of 2023. The global Parkinson's Disease drug market is expected to reach $10.4 billion by 2031. Buntanetap is also being explored in an ongoing phase 2/3 study for the treatment of patients with mild to moderate Alzheimer's Disease. Annovis Bio had $16.8 million in cash as of March 31, 2023; enough cash to fund its operations into Q1 of 2024 and will likely need to raise additional cash before end of 2023. Read the full article on Seeking Alpha
Seeking Alpha • Feb 08

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Annovis Bio (NYSE:ANVS) announced Wednesday the EU approval to bring additional 48 trial sites for its Phase 3 study for lead candidate buntanetap in the treatment of Parkinson's disease ("PD"). With 50 clinical trial sites open in the U.S., the clinical-stage biotech is currently enrolling patients for the randomized study, which tests buntanetap 10mg or 20mg vs. placebo in addition to standard of care for six months. "We are pleased to significantly expand our geographic reach with the addition of these EU sites that gives us the ability to efficiently enroll European patients in our study," Chief Executive of Annovis (ANVS) Maria Maccecchini remarked. The company intends to enroll early PD patients in these additional trial sites, spread across countries such as Italy, Spain, Hungary, Poland, and Germany. An interim readout is expected in Q2 2023 if there is a sufficient number of patients who have received two months of therapy. Seeking Alpha contributor Terry Chrisomalis issued a Strong Buy rating on Annovis (ANVS) last year, citing the potential of buntanetap in PD.
Analysis Article • Jan 28

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 25

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Clinical stage biotech Annovis Bio (NYSE:ANVS) traded higher in the morning hours Wednesday after the company highlighted "strong" patient enrollment in its Phase 3 trial for Parkinson's disease (PD) candidate buntanetap. "We are very pleased with the pace of enrollment in our Phase 3 study, designed to assess the safety and efficacy of buntanetap in early-stage Parkinson's patients," Chief Executive Maria Maccecchini noted. The company has arranged an interim data analysis in Q2 2023 to see if its original target of 150 patients per arm will be enough to demonstrate a treatment effect. "Based on the current enrollment, the Company anticipates having a sufficient number of patients who have received two months of therapy to conduct an interim analysis in the second quarter of 2023," Annovis (ANVS) added. Buntanetap, formerly known as ANVS401 or Posiphen, has potential not only in PD but also in Alzheimer's, Seeking Alpha contributor Terry Chrisomalis points out.
Seeking Alpha • Oct 06

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Summary Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026. Potential to receive clearance to initiate a phase 3 study using buntanetap for the treatment of patients with Alzheimer's Disease if end of phase 2 meeting goes well. Other drugs in the pipeline include ANVS301 for advanced Alzheimer's Disease/dementia and ANVS405 for traumatic brain injury and stroke.
Analysis Article • Sep 15

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has Maria Maccecchini's remuneration changed compared to Annovis Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$41m

Dec 31 2025US$808kUS$808k

-US$29m

Sep 30 2025n/an/a

-US$25m

Jun 30 2025n/an/a

-US$30m

Mar 31 2025n/an/a

-US$29m

Dec 31 2024US$2mUS$735k

-US$25m

Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$3mUS$668k

-US$56m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$3mUS$636k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$9mUS$510k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$420k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$120kUS$120k

-US$991k

Compensation vs Market: Maria's total compensation ($USD808.00K) is about average for companies of similar size in the US market ($USD627.03K).

Compensation vs Earnings: Maria's compensation has been consistent with company performance over the past year.

CEO

Maria Maccecchini (74 yo)

18yrs
Tenure
US$808,000
Compensation

Dr. Maria L. Maccecchini, Ph D., is Independent Director of Treventis Corporation. She serves as Independent Director of Lantern Pharma Inc. from June 08, 2022.She is the Founder of Annovis Bio, Inc. and...

Leadership Team

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder18yrsUS$808.00k3.5%
$ 3.3m
Cheng Fang
Senior Vice President of Research & Development4.3yrsno datano data
Eve Damiano
Senior Vice President of Regulatory Operations4.3yrsno datano data
Blake Jensen
Head of Quality1.8yrsno datano data
Hilda Maibach
Senior Vice President of Statistics1.8yrsno datano data
4.3yrs
Average Tenure

Experienced Management: ANVS's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Maria Maccecchini
Founder18yrsUS$808.00k3.5%
$ 3.3m
Michael M. Hoffman
Independent Chairman of the Board12.3yrsUS$98.49k10.14%
$ 9.6m
Jeffrey Cummings
Chief Medical Advisor & Member of Scientific Advisory Boardno datano datano data
Gregory Petsko
Member of Scientific Advisory Board9.3yrsno datano data
Reid McCarthy
Independent Director5.1yrsUS$68.15k0.027%
$ 25.5k
Sidney Strickland
Chairman of Scientific Advisory Board9.3yrsno datano data
Mark White
Director10.3yrsUS$34.82k0.18%
$ 167.5k
Claudine Bruck
Independent Director11.3yrsUS$34.82k0.040%
$ 37.5k
10.3yrs
Average Tenure
72.5yo
Average Age

Experienced Board: ANVS's board of directors are seasoned and experienced ( 10.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 19:30
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Annovis Bio, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.
Jason McCarthyMaxim Group